Speaker illustration

Doctor Elliot Barnathan

Janssen R and D LLC, Spring House (United States of America)

Member of:

European Society of Cardiology

Elliot Barnathan, MD, FACC, FAHA is a senior director at Janssen Research and Development, LLC and is responsible for clinical development for rivaroxaban worldwide. He has most recently lead a program for the development of rivaroxaban for extended thromboprophylaxis for hospitalized medically ill patients and is currently leading a study evaluating the use of rivaroxaban in symptomatic COVID-19 outpatients at risk for venous and arterial thrombotic events. He spent 10 years on the faculty at the University of Pennsylvania with a primary focus on endothelial cell biology and the plasminogen activator system. He currently holds an appointment as an Adjunct Associate Professor of Medicine at the University of Pennsylvania School of Medicine. He has worked at Centocor/Janssen for more than 20 years developing drugs in a variety for areas include acute ischemic stroke and stroke prevention.

Efficacy of rivaroxaban compared to standard of care in preventing ischemic stroke in adults with coronary or peripheral vascular disease: an integrated analysis using patient-level data

Event: ESC Congress 2020

Topic: Prevention

Session: Stroke and Atherosclerosis – From Risk Evaluation to Treatment


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb